Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.

ABSTRACT:

Background

Melanoma is the most aggressive and deadly form of skin cancer with increasing case numbers worldwide. The development of inhibitors targeting mutated BRAF (found in around 60% of melanoma patients) has markedly improved overall survival of patients with late-stage tumors, even more so when combined with MEK inhibitors targeting the same signaling pathway. However, invariably patients become resistant to this targeted therapy resulting in rapid progression with treatment-refractory disease. The purpose of this study was the identification of new kinase inhibitors that do not lead to the development of resistance in combination with BRAF inhibitors (BRAFi), or that could be of clinical benefit as a 2nd line treatment for late-stage melanoma patients that have already deve

SUBMITTER: Margue C 

PROVIDER: S-EPMC6364417 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature